| Company Name: | Dendreon Corporation | | Ticker Symbol: | DNDN | | | WWW Address: | www.dendreon.com | | CEO: | Dr. Mitchell H. Gold, M.D. | | No. of Employees: | 198 | | Common Issue Type: | CS | | Business Description: | A biotechnology company, which is focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
|
| | | Industry Information: | DRUGS - Biotechnology [more like this] |
| | Price | Day Change | Bid | Ask | Open | High | Low | Volume | | 27.54 |  -0.47 | 27.25 | 28.1 | 28.3 | 28.39 | 27.31 | 2109567 |
| Market Cap (mil) | Shares Outstanding (mil) | Beta | EPS | DPS | P/E | Yield | 52-Wks-Range |
| 3,191.9 | 115.9 | 4.33 | -0.79 | 0.00 | 0.0 | 0.0 | 30.42 - 2.55 |
| | KEY FIGURES (Latest Twelve Months - LTM) | | Yesterday's Close | 27.54 | $ | | PE Ratio - LTM | 0.0 | |
| Market Capitalisation | 3,192.9 | mil |
| Latest Shares Outstanding | 115.9 | mil |
| Earnings pS (EPS) | -0.79 | $ |
| Dividend pS (DPS) | 0.00 | ¢ |
| Dividend Yield | 0.0 | % |
| Dividend Payout Ratio | 0 | % |
| Revenue per Employee | 561 | $ |
| Effective Tax Rate | 0.0 | % |
| Float | 113.7 | mil |
| Float as % of Shares Outstanding | 98.3 | % |
| Foreign Sales | 0 | mil |
| Domestic Sales | 0 | mil |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 24,915.70 | % |
| Research & Devlopment (R&D) as % of Revenue | 48,488.00 | % |
| Gross Profit Margin | 0.0 | % |
| EBITDA Margin | 0.0 | % |
| Pre-Tax Profit Margin | 0.0 | % |
| Assets Turnover | 0.0 | % |
| Return on Assets (ROA) | -55.4 | % |
| Return on Equity (ROE) | 0.0 | % |
| Return on Capital Invested (ROCI) | -105.3 | % |
| Current Ratio | 1.6 | |
| Leverage Ratio (Assets/Equity) | 3.0 | |
| Interest Cover | 0.0 | |
| Total Debt/Equity (Gearing Ratio) | 0.58 | |
| LT Debt/Total Capital | 36.0 | % |
| Working Capital pS | 0.89 | $ |
| Cash pS | 1.49 | $ |
| Book-Value pS | 1.03 | $ |
| Tangible Book-Value pS | 1.03 | $ |
| Cash Flow pS | -1.65 | $ |
| Free Cash Flow pS | -0.85 | $ |
 |
| KEY FIGURES (LTM): Price info |
| Price/Book Ratio | 26.85 | |
| Price/Tangible Book Ratio | 26.85 | |
| Price/Cash Flow | -16.6 | |
| Price/Free Cash Flow | -32.6 | |
| P/E as % of Industry Group | 0.0 | % |
| P/E as % of Sector Segment | 0.0 | % |
| | | Balance Sheet (at a glance) in Millions |
| | | | | | DIVIDEND INFO | | Type of Payment | - |
| Dividend Rate | 0.00 |
| Current Dividend Yield | 0.0 |
| 5-Y Average Dividend Yield | 0.0 |
| Payout Ratio | 0.0 |
| 5-Y Average Payout Ratio | 0.0 |
| |
| |
| |
| |
| |
|  | | Share price performance previous 3 years |
|
 | | | Share price performance intraday |
|
 | | | | | PRICE/VOLUME | High | Low | Close | % Price Chg | % Price Chg vs. Mkt. | Avg. Daily Vol | Total Vol |
| 1 Week | - | - | - | -1.7 | 97 | 19,653 | 20,643 |
| 4 Weeks | 30.10 | 24.80 | 25.27 | 9.0 | 102 | 23,487 | 375,800 |
| 13 Weeks | 30.42 | 22.57 | 23.78 | 15.8 | 108 | 31,027 | 1,861,625 |
| 26 Weeks | 30.42 | 21.25 | 22.67 | 21.5 | 101 | 31,345 | 3,886,794 |
| 52 Weeks | 30.42 | 2.55 | 4.88 | 464.3 | 457 | 40,748 | 10,105,425 |
| YTD | 30.42 | 2.55 | - | 501.3 | 491 | 43,752 | 9,887,979 |
| Moving Average | 5-Days | 10-Days | 10-Weeks | 30-Weeks | 200-Days | Beta (60-Mnth) | Beta (36-Mnth) |
| 28.34 | 28.75 | 27.87 | 24.98 | 20.07 | 4.33 | 4.93 |
| | | | GROWTH RATES | 5-Year
Growh | R² of 5-Year Growth | 3-Year
Growth |
| Revenue | -49.40 | 59.4 | -29.76 |
| Income | 0.00 | 0.0 | 0.00 |
| Dividend | 0.00 | 0.0 | 0.00 |
| Capital Spending | 17.43 | NA | -20.68 |
| R&D | -1.92 | NA | -11.33 |
| Normalized Inc. | 0.00 | NA | 0.00 |
| | | CHANGES | YTD vs.
Last YTD | Curr Qtr vs.
Qtr 1-Yr ago | Annual vs.
Last Annual |
| Revenue % | -3.6 | -3.8 | -85.1 |
| Earnings % | 0.0 | 0.0 | 0.0 |
| EPS % | 0.0 | 0.0 | 0.0 |
| EPS $ | -1.08 | -0.11 | 0.41 |
| | | | SOLVENCY RATIOS | | SHORT-TERM SOLVENCY RATIOS (LIQUIDITY) |
| Net Working Capital Ratio | 57.25 |
| Current Ratio | 4.2 |
| Quick Ratio (Acid Test) | 4.0 |
| Liquidity Ratio (Cash) | 4.10 |
| Receivables Turnover | 0.0 |
| Average Collection Period | 0 |
| Working Capital/Equity | 312.0 |
| Working Capital pS | 0.86 |
| Cash-Flow pS | -0.67 |
| Free Cash-Flow pS | -0.74 |
| FINANCIAL STRUCTURE RATIOS |
| Altman's Z-Score Ratio | 14.45 |
| Financial Leverage Ratio (Assets/Equity) | 5.5 |
| Debt Ratio | 81.7 |
| Total Debt/Equity (Gearing Ratio) | 3.54 |
| LT Debt/Equity | 3.45 |
| LT Debt/Capital Invested | 77.8 |
| LT Debt/Total Liabilities | 77.6 |
| Interest Cover | 0.0 |
| Interest/Capital Invested | 4.28 |
| | | | VALUATION RATIOS | | MULTIPLES |
| PQ Ratio | 15.09 |
| Tobin's Q Ratio | 21.69 |
| Current P/E Ratio - LTM | 0.00 |
| Enterprise Value (EV)/EBITDA | -49.48 |
| Enterprise Value (EV)/Free Cash Flow | -42.32 |
| Dividend Yield | 0.0 |
| Price/Tangible Book Ratio - LTM | 26.85 |
| Price/Book Ratio - LTM | 26.85 |
| Price/Cash Flow Ratio | -16.6 |
| Price/Free Cash Flow Ratio - LTM | -32.6 |
| Price/Sales Ratio | 29,564.10 |
| P/E Ratio (1 month ago) - LTM | 0.0 |
| P/E Ratio (26 weeks ago) - LTM | 0.0 |
| P/E Ratio (52 weeks ago) - LTM | 0.0 |
| 5-Y High P/E Ratio | 0.0 |
| 5-Y Low P/E Ratio | 0.0 |
| 5-Y Average P/E Ratio | 0.0 |
| Current P/E Ratio as % of 5-Y Average P/E | 0 |
| P/E as % of Industry Group | 0.0 |
| P/E as % of Sector Segment | 0.0 |
| Current 12 Month Normalized P/E Ratio - LTM | 0.0 |
| PER SHARE FIGURES |
| LT Debt pS | 0.95 |
| Current Liabilities pS | 0.27 |
| Tangible Book Value pS - LTM | 1.03 |
| Book Value pS - LTM | 1.03 |
| Capital Invested pS | 1.04 |
| Cash pS - LTM | 1.49 |
| Cash Flow pS - LTM | -1.65 |
| Free Cash Flow pS - LTM | -0.85 |
| Earnings pS (EPS) | -0.79 |
| | | | OPERATING RATIOS | | PROFITABILITY RATIOS |
| Free Cash Flow Margin | -65,654.95 |
| Free Cash Flow Margin 5YEAR AVG | -30,073.09 |
| Net Profit Margin | 0.0 |
| Net Profit Margin - 5YEAR AVRG. | 0.0 |
| Equity Productivity | 0.00 |
| Return on Equity (ROE) | 0.0 |
| Return on Equity (ROE) - 5YEAR AVRG. | 0.0 |
| Capital Invested Productivity | 0.00 |
| Return on Capital Invested (ROCI) | -59.6 |
| Return on Capital Invested (ROCI) - 5YEAR AVRG. | -54.0 |
| Assets Productivity | 0.00 |
| Return on Assets (ROA) | -48.7 |
| Return on Assets (ROA) - 5YEAR AVRG. | -46.7 |
| Gross Profit Margin | 0.0 |
| Gross Profit Margin - 5YEAR AVRG. | 0.0 |
| EBITDA Margin - LTM | 0.0 |
| EBIT Margin - LTM | 0.0 |
| Pre-Tax Profit Margin | 0.0 |
| Pre-Tax Profit Margin - 5YEAR AVRG. | 0.0 |
| Effective Tax Rate | 0.0 |
| Effective Tax Rate - 5YEAR AVRG. | 0.4 |
| EFFICIENCY RATIOS |
| Cash Conversion Cycle | 0 |
| Revenue per Employee | 561 |
| Net Income per Employee | -361,838 |
| Average Collection Period | 0 |
| Receivables Turnover | 0.0 |
| Day's Inventory Turnover Ratio | 0 |
| Inventory Turnover | 0.0 |
| Inventory/Sales | 0.0 |
| Accounts Payble/Sales | 213.51 |
| Assets/Revenue | 0.00 |
| Net Working Capital Turnover | 0.00 |
| Fixed Assets Turnover | 0.00 |
| Total Assets Turnover | 0.0 |
| Revenue per $ Cash | 0.00 |
| Revenue per $ Plant | 0.00 |
| Revenue per $ Common Equity | 0.00 |
| Revenue per $ Capital Invested | 0.00 |
| Selling, General & Adm/tive (SG&A) as % of Revenue | 18471.2 |
| SG&A Expense as % of Revenue - 5YEAR AVRG. | 1752.2 |
| Research & Devlopment (R&D) as % of Revenue | 45122.5 |
| R&D Expense as % of Revenue - 5YEAR AVRG. | 45122.5 |
|
|  
| | |  |  | |
| |